Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

R347

fc2980c9-1554-517f-a841-c12d6661cc78

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
overall_survival_months
120
sex
Male

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

No GSVA scores available for this sample.

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R377
bladder-landscape@3
0.843
2AUR-AFKB-TTP1-A-10-0-R-A741-41
breast-umap@18
D0.794
3SRR10900594
melanoma-umap@29
0.793
4MNG17
mng-umap@100
0.788
5TCGA-BH-A1ET-01A-11R-A137-07
breast-umap@18
B0.769
6MNG1173
mng-umap@100
0.766
7R352
bladder-landscape@3
0.762
820020052.LumA
breast-umap@18
A0.761
9MNG500
mng-umap@100
0.760
10AUR-AER8-TTP1-A-1-0-R-A741-41
breast-umap@18
D0.759

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 13 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.370Remibrutinib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
TGF_BETA_SIGNALING0.240Inavolisib— uncovered
ANDROGEN_RESPONSE0.220Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.220Inavolisib— uncovered
UV_RESPONSE_DN0.210Inavolisib— uncovered
PANCREAS_BETA_CELLS0.120Cobimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.060Inavolisib— uncovered
HEME_METABOLISM0.060Temsirolimus— uncovered
COMPLEMENT0.020Inavolisib— uncovered
KRAS_SIGNALING_DN0.020Remibrutinib— uncovered
COAGULATION0.010Binimetinib— uncovered
HYPOXIA0.010Idelalisib— uncovered